Ankur Drugs & Pharma Peer Comparison

NSE: ANKURDRUGS | BSE: 531683

₹3.65

₹-0.15 (-3.95%)

As on 10-Sep-2013IST

Market cap

₹8 Cr

Revenue (TTM)

₹143 Cr

P/E Ratio

P/B Ratio

-0

Div. Yield

0 %

Edit

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	8	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	143	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-247.35	414.00	288.22	-371.81	387.35
Net Margin (%)	-164.83	11.23	14.79	-3.93	26.01
RoE (%)	-100.00	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	-0.04	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	151.49	4,350.50	34.80	--	33.90
Total Income	169.03	4,375.84	34.80	--	34.61
Total Expenditure	184.23	2,996.79	25.65	--	30.42
EBITDA	-32.74	1,353.71	9.15	--	3.48
Depreciation	61.19	115.07	2.71	--	1.05
EBIT	-93.94	1,238.64	6.44	--	2.42
Interest	75.71	269.02	2.51	--	1.10
Other Income	17.54	25.34	0.42	--	0.71
Exceptional Items	-136.37	-473.77	--	--	--
Profit before Tax	-288.47	521.19	3.93	--	2.03
Provision for Tax	19.02	221.74	1.40	--	0.68
Profit after Tax	-307.49	299.45	2.52	--	1.35

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	238.31	1,471.02	37.49	--	6.11
Minority Interest	--	--	--	--	--
Non-Current Liabilities	671.39	2,891.88	5.39	--	0.04
Current Liabilities	618.95	1,890.94	24.92	--	15.82
Total Liabilities	1,528.65	6,253.84	67.79	--	22.09

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,426.91	3,772.33	47.64	--	5.51
Current Assets	63.05	2,481.51	20.15	--	16.45
Total Assets	1,528.65	6,253.84	67.79	--	22.09
Total Debt*	988.24	3,492.50	19.14	--	6.41
Net Current Assets	-555.90	590.57	-4.76	--	0.63
Contingent Liabilities	12.89	46.91	0.71	--	--

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	3.20	1,343.83	5.07	--	--
Cash Flow from Investing Activities	23.96	-305.45	-4.60	--	--
Cash from Financing Activities	-26.92	-826.56	-0.83	--	--
Net Cash Inflow / Outflow	0.25	211.82	-0.36	--	0.00

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-16.03	16.20	12.09	--	25.61
ROE (%)	-328.47	66.74	14.65	--	24.87
ROA (%)	-18.59	4.97	4.06	--	6.42
EBIT Margin (%)	-10.03	31.70	26.29	--	12.34
Net Margin (%)	-181.91	6.84	7.25	--	3.90
Cash Profit Margin (%)	-161.65	9.52	15.04	--	6.56

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-81.63	15.97	65.29	--	21.86
EBIT Growth (%)	-111.27	29.05	42.04	--	27.63
Net Profit Growth (%)	-346.89	212.90	6.25	--	7.55
EPS Growth (%)	-346.89	278.36	6.25	--	7.55
Book Value Growth (%)	-123.56	253.45	15.81	--	28.51

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	17.64	0.00	--	0.00
Price / Book Value	-0.49	9.37	0.00	--	0.00
Dividend Yield (%)	0.00	0.00	--	--	--
EV/EBITDA	-66.76	7.33	4.36	--	1.71
Market Cap (₹ Cr)	28.53	6,555.46	0.00	--	0.00

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-17.12	2.39	0.51	--	1.05
Short term debt to equity ratio	0.48	0.18	0.21	--	0.88
Current Ratio	0.10	1.31	0.81	--	1.04
Quick Ratio	0.07	0.84	0.77	--	0.66
Interest Coverage	-2.81	2.94	2.57	--	2.86

	Ankur Drugs & Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	20.96	17.44	42.51	--	24.27
Asset Turnover	0.09	0.72	0.56	--	1.74
Receivable days	83.75	57.17	120.33	--	81.45
Inventory Days	219.24	67.16	9.04	--	45.36
Payable days	432.78	116.25	535.25	--	134.63
Cash Conversion Cycle	-129.79	8.07	-393.94	--	-7.82

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.